

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. Three separate but related issues were identified by a stakeholder.

1. There is an association between socio-economic status and lung cancer mortality.
2. EGFR mutations are more common in women and people with Asian heritage
3. Existence of stigma around lung cancer due to the widely acknowledged association between smoking and lung cancer (and the accompanying perception that it is “self-inflicted”). EGFR mutations are not associated with smoking. Stigma could contribute to diagnosis or treatment delaying behaviour.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in prevalence of a condition in different groups cannot be addressed by a technology appraisal committee during an appraisal. The committee will consider whether there are any relevant equality issues affecting its decision as part of the appraisal process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No changes have been agreed to highlight these potential issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): ...Lorna Dunning

Date: 23/10/24